RU2016136504A - ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ - Google Patents
ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ Download PDFInfo
- Publication number
- RU2016136504A RU2016136504A RU2016136504A RU2016136504A RU2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- eribulin
- solvate
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947398P | 2014-03-03 | 2014-03-03 | |
| US61/947,398 | 2014-03-03 | ||
| PCT/US2015/018335 WO2015134399A1 (en) | 2014-03-03 | 2015-03-02 | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016136504A true RU2016136504A (ru) | 2018-04-03 |
| RU2016136504A3 RU2016136504A3 (enExample) | 2018-10-25 |
Family
ID=54055761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016136504A RU2016136504A (ru) | 2014-03-03 | 2015-03-02 | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170071903A1 (enExample) |
| EP (1) | EP3113775A4 (enExample) |
| JP (1) | JP2017507151A (enExample) |
| KR (1) | KR20160135230A (enExample) |
| CN (1) | CN106029070A (enExample) |
| AU (1) | AU2015225436A1 (enExample) |
| CA (1) | CA2940983A1 (enExample) |
| IL (1) | IL247586A0 (enExample) |
| RU (1) | RU2016136504A (enExample) |
| SG (1) | SG11201607298QA (enExample) |
| WO (1) | WO2015134399A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| CN105338977B (zh) | 2013-06-26 | 2018-10-16 | 卫材R&D管理有限公司 | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 |
| WO2017188350A1 (ja) * | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| ES3075649T3 (en) | 2019-07-26 | 2026-08-06 | Eisai R&D Man Co Ltd | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CN106822083A (zh) * | 2009-08-27 | 2017-06-13 | 生物学特性有限公司 | 用于治疗增生性疾病的联合疗法 |
| WO2012119077A1 (en) * | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| CN104684579A (zh) * | 2012-04-02 | 2015-06-03 | 梅里麦克制药股份有限公司 | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 |
-
2015
- 2015-03-02 RU RU2016136504A patent/RU2016136504A/ru unknown
- 2015-03-02 AU AU2015225436A patent/AU2015225436A1/en not_active Abandoned
- 2015-03-02 EP EP15758504.3A patent/EP3113775A4/en not_active Withdrawn
- 2015-03-02 US US15/123,476 patent/US20170071903A1/en not_active Abandoned
- 2015-03-02 CN CN201580011593.4A patent/CN106029070A/zh active Pending
- 2015-03-02 SG SG11201607298QA patent/SG11201607298QA/en unknown
- 2015-03-02 CA CA2940983A patent/CA2940983A1/en not_active Abandoned
- 2015-03-02 JP JP2016555458A patent/JP2017507151A/ja active Pending
- 2015-03-02 WO PCT/US2015/018335 patent/WO2015134399A1/en not_active Ceased
- 2015-03-02 KR KR1020167027369A patent/KR20160135230A/ko not_active Withdrawn
-
2016
- 2016-08-31 IL IL247586A patent/IL247586A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016136504A3 (enExample) | 2018-10-25 |
| JP2017507151A (ja) | 2017-03-16 |
| IL247586A0 (en) | 2016-11-30 |
| WO2015134399A1 (en) | 2015-09-11 |
| US20170071903A1 (en) | 2017-03-16 |
| KR20160135230A (ko) | 2016-11-25 |
| SG11201607298QA (en) | 2016-09-29 |
| CA2940983A1 (en) | 2015-09-11 |
| AU2015225436A1 (en) | 2016-09-08 |
| EP3113775A4 (en) | 2017-08-23 |
| CN106029070A (zh) | 2016-10-12 |
| EP3113775A1 (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer | |
| Wu et al. | Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer | |
| JP2017507151A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| Jia et al. | Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity | |
| JP2019511553A (ja) | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ | |
| JP2011515397A5 (enExample) | ||
| JP7530116B2 (ja) | エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物 | |
| Ma et al. | IPM712, a vanillin derivative as potential antitumor agents, displays better antitumor activity in colorectal cancers cell lines | |
| RU2017134148A (ru) | Комбинация тасквинимода или его фармацевтически приемлемой соли и ингибитора pd-1 и/или pd-l1 для применения в качестве лекарственного средства | |
| Lee et al. | Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study | |
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| JP2017516802A5 (enExample) | ||
| Ding et al. | SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells | |
| RU2016148441A (ru) | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом | |
| JP6997919B2 (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| EP3302488A1 (en) | Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | |
| Torki et al. | Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells | |
| Selvaggi et al. | Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities | |
| JP2019513812A5 (enExample) | ||
| Mountzios et al. | Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non‐Platinum‐Containing Regimens, and Molecular Targeted Agents | |
| RU2012148706A (ru) | Комбинация органичемких соединений | |
| JP7468829B2 (ja) | 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤 | |
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| US10159659B2 (en) | Predicting response to cancer therapy |